Tradestie Institutional Equity Comparison Engine

SPRO vs AKTS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SPRO Overall Edge

SPRO Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Spero Therapeutics, Inc. Common Stock (SPRO) driven by superior Valuation, Growth & Margin, Options & Structure while AKTS counters with relative strength in Momentum & Technical. Fundamentally, SPRO trades at N/M Forward P/E with 14.1% operating margin (-95.6% YoY revenue) versus AKTS at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, SPRO sits in BREAKDOWN (24th %ile IV; Dealer Gamma Walls on Pro) against AKTS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner SPRO
SPRO N/M vs AKTS N/M Fwd P/E
Growth & Margin Winner SPRO
Op Margin 14.1% vs N/A ยท YoY -95.6% vs N/A
Momentum & Technical Winner AKTS
1Y -62.3% vs -26.1% ยท 52W Pos 1% vs 13%
Options & Structure Winner SPRO
BREAKDOWN (24th %ile IV) vs UNCLASSIFIED (N/A IV)
SPRO NASDAQ
Spero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.92
-7.99% 1D
Market Cap $58.8M
1M Return -16.36%
1Y Return -62.3%
Forward P/E N/M
Unified AI Score
47.8 / 100 HOLD
Tech 39.0 Fund 53.0 Flow 66.0 Mom 60.0
AKTS US Equity
AKTS
Institutional Equity
$16.55
-0.42% 1D
Market Cap N/A
1M Return +9.89%
1Y Return -26.12%
Forward P/E N/M
Unified AI Score
30.6 / 100 SELL
Tech 20.0 Fund 36.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SPRO -62.3% AKTS -26.12% Spread: +37.8 pp (AKTS Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SPRO TTM Op. Margin: 14.1% AKTS TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SPRO vs AKTS. Trailing 12-month operating profitability (SPRO 14.1% vs AKTS N/A) and valuation multiples (SPRO N/M vs AKTS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SPRO (7) vs AKTS (2)
Institutional Metric SPRO AKTS Criterion Row Winner
Market Capitalization Scale $58.8M N/A Larger Scale SPRO
Trailing P/E Ratio Valuation 7.2x N/M Lower Multiple SPRO
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -95.6% N/A Higher Growth SPRO
Operating Margin (TTM) Profitability 14.1% N/A Higher Margin SPRO
Net Profit Margin Profitability 15.7% N/A Higher Margin SPRO
Return on Equity (ROE) Capital Efficiency 19.2% N/A Higher ROE SPRO
52-Week Range Position Momentum 1% ($1โ€“$3) 13% ($14โ€“$34) Stronger Trend AKTS
Beta / 30D Volatility Risk Regime 1.75ฮฒ ยท 70% Vol 1.35ฮฒ ยท 67% Vol Lower Realized Risk AKTS
Unified Institutional Score Composite Signal 47.8 / 100 (HOLD) 30.6 / 100 (SELL) Higher Composite SPRO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SPRO vs AKTS Buy Guide
SPRO BREAKDOWN
120d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 24th %ile
IV Regime Compressed (<25th %ile)
Live SPRO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AKTS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live AKTS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SPRO nor AKTS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.